Skip to content Skip to footer

AbbVie to Acquire Capstan Therapeutics for ~$2.1B

Shots:AbbVie has entered into a definitive agreement to acquire Capstan Therapeutics, including its P-I CPTX2309 and proprietary tLNP platform for in vivo RNA delivery to treat B-cell-mediated autoimmune diseasesAs per the deal, Capstan will receive up to $2.1B in cash, pending customary closing conditions and regulatory approvalsCPTX2309 is a tLNP delivering mRNA…

Read more

Know Your Investor: Alexandria Venture (May’25 Edition)

Know Your Investor: Alexandria Venture (May’25 Edition)

Shots:    Welcome to the 2025 edition of Know Your Investor, spotlighting leading venture capital firms driving innovation in healthcare. This edition features Alexandria Venture Investments, a firm committed to supporting disruptive life science companies that aim to improve human health. In 2024, the firm invested approximately $2.7B across six public and private funding rounds, adding…

Read more